We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

40 hedge funds and large institutions have $1.15M invested in Aspire Biopharma Warrant in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

14% more funds holding

Funds holding: 35 → 40 (+5)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

56% less capital invested

Capital invested by funds: $2.63M → $1.15M (-$1.48M)

Holders
40
Holders Change
+5
Holders Change %
+14.29%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
3
Closed
2
Calls
$2.12M
Puts
–
Net Calls
+$2.12M
Net Calls Change
+$5K

Top Buyers

Rank Fund Capital Flow
1
HIM
HGC Investment Management
Ontario, Canada
+$3.67K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.25K
3
Walleye Capital
Walleye Capital
New York
+$1.17K
4
EFI
EHP Funds Inc
Canada
+$918
5
PC
Periscope Capital
Ontario, Canada
+$918

Top Sellers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$8.36K
2
DCM
Difesa Capital Management
New York
-$3.13K
3
PMAM
Picton Mahoney Asset Management
Ontario, Canada
-$918
4
AA
AQR Arbitrage
Connecticut
-$133
5
CS
Clear Street
New York
-$58
Name Holding Trade Value Shares
Change 		Change in
Stake
FSI
26
Flow State Investments
Illinois
$3.01K +$184 +5,000 +9%
PMAM
27
Picton Mahoney Asset Management
Ontario, Canada
$3K -$918 -25,000 -33%
CS
28
Clear Street
New York
$2.73K -$58 -1,583 -3%
ACM
29
Atalaya Capital Management
New York
$2.5K – – –
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$1.7K +$1.25K +33,933 New
Walleye Capital
31
Walleye Capital
New York
$1.6K +$1.17K +32,000 New
OAC
32
OMERS Administration Corp
Ontario, Canada
$1.37K – – –
EFI
33
EHP Funds Inc
Canada
$1.25K +$918 +25,000 New
MTCM
34
Mint Tower Capital Management
Netherlands
$1K – – –
Walleye Trading
35
Walleye Trading
New York
$902 +$661 +18,000 New
LCM
36
Landscape Capital Management
New Jersey
$751 +$550 +14,999 New
BI
37
Bulldog Investors
New Jersey
$626 – – –
PI
38
PEAK6 Investments
Illinois
$626 – – –
AC
39
Athos Capital
Hong Kong
$264 – – –
IRC
40
Investors Research Corp
Georgia
$1 – – –
Balyasny Asset Management
41
Balyasny Asset Management
Illinois
– -$8.36K -200,000 Closed
DCM
42
Difesa Capital Management
New York
– -$3.13K -75,000 Closed
1
2

ASBPW Hedge Fund Activity: Q2 2023 in Review

40 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q2 2023, worth a combined $1.15M — down 56% from $2.63M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ASBPW positions and 2 closed out — a net gain of 5 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was HGC Investment Management, opening a new position worth an estimated $3.67K. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $8.36K sold.

  • 40 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q2 2023, up from 35 in Q1 2023.
  • Funds reported $1.15M of Aspire Biopharma Warrant stock for Q2 2023, down 56% quarter-over-quarter.
  • 7 funds opened new Aspire Biopharma Warrant positions in Q2 2023 and 2 closed out, a net change of +5 holders.
  • The largest Aspire Biopharma Warrant buyer in Q2 2023 was HGC Investment Management, an estimated $3.67K added.
  • The largest Aspire Biopharma Warrant seller in Q2 2023 was Balyasny Asset Management, an estimated $8.36K sold.

Based on aggregated 13F filings for Q2 2023.